title: A Retrospective Analysis of Drug Fever Diagnosed during Infectious Disease Consultation.
abstract: OBJECTIVE
  To clarify the current situation concerning drug fever (DF) in Japan, we retrospectively analyzed patients undergoing infectious disease consultation at our institution.
  
  
  METHODS
  Between April 2014 and May 2015, we extracted the records of DF patients from among 388 patients who had obtained infectious disease consultations in Kurume University Hospital. We reviewed their medical charts and summarized the characteristics of DF.
  
  
  RESULTS
  This study included the records of 16 patients. Clinical signs (relative bradycardia, the duration of the drug administration before becoming febrile, and the interval between the discontinuation of a drug and the alleviation of a fever), and laboratory tests (varied white blood cell count, low level of C-reactive protein, and a mild elevation of transaminases) were compatible with those from previous reports. Among the drug-confirmed cases, five involved the use of glycopeptides (vancomycin: 3, teicoplanin: 2), which were considered to be uncommon causes, and the another five cases involved the use of β-lactams. In addition, the procalcitonin levels were either negative or low (≤0.25 ng/mL) in 10 of the 11 procalcitonin-measured cases.
  
  
  CONCLUSIONS
  Our findings demonstrated that glycopeptides, similar to β-lactams, may be the origin of DF. Furthermore, procalcitonin may be helpful in the diagnosis of DF, but only in combination with other detailed examinations.
authors.affiliation: Department of Infection Control and Prevention, Kurume University School of Medicine, Japan.
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Yaita
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Sakai
authors.forename: Kenji
authors.initials: K
authors.lastname: Masunaga
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Watanabe
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D001919:Bradycardia / Q000139:chemically induced* / Q000276:immunology; D002097:C-Reactive Protein / Q000378:metabolism; D002116:Calcitonin / Q000097:blood; D015740:Calcitonin Gene-Related Peptide; D003141:Communicable Diseases / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D005334:Fever / Q000139:chemically induced* / Q000276:immunology; D006785:Hospitals, University; D006801:Humans; D007564:Japan / Q000453:epidemiology; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011498:Protein Precursors / Q000097:blood; D012017:Referral and Consultation; D012189:Retrospective Studies
chemical_list: D000900:Anti-Bacterial Agents; D015415:Biomarkers; C000606589:CALCA protein, human; D011498:Protein Precursors; D002116:Calcitonin; D002097:C-Reactive Protein; D015740:Calcitonin Gene-Related Peptide